Catalyst Pharmaceuticals, Inc. CPRX is slated to report first-quarter 2019 results.
The company’s earnings surpassed expectations in one of the previous four quarters, the average positive surprise being 2.08%.
Catalyst Pharma’s share price has skyrocketed 195.9% compared with the industry’s growth of 9.6% year to date.
Let's see how things are shaping up for this announcement.
Factors to Consider
Catalyst Pharma’s lead product, Firdapse (amifampridine) tablets, secured the FDA approval for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults last November. Firdapse is the first treatment for LEMS that got an FDA nod. This achievement lends a big boost to the company. Firdapse was launched in January 2019. Investors’ focus will be on the revenues generated by this product during the quarter under review along with its launch results.
The company is also working on developing Firdapse for additional indications. It is evaluating Firdapse for the treatment of MuSK-antibody positive MG and also certain types of congenital myasthenic syndromes (“CMS”) in the pediatric population (2-17 years) apart from addressing Spinal Muscular Atrophy (SMA) type III. We expect updates from these studies in the upcoming quarterly release.
Last December, the company signed a definitive agreement with Endo International plc's ENDP subsidiary, Endo Ventures Limited, for further development and commercialization of generic Sabril tablets through Endo’s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical. Pursuant to this deal, Catalyst Pharma will receive an up-front payment and milestone fees based on the achievement of regulatory approvals and a fair share of defined net profits upon commercialization. We expect latest news on this in the impending quarterly report.
What the Model Indicates
The proven Zacks model does not conclusively show that Catalyst Pharma is likely to beat on earnings in the to-be-reported quarter. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Catalyst Pharma has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Catalyst Pharma carries a Zacks Rank #3, which increases the predictive power of ESP. However, a 0.00% ESP in the combination makes surprise prediction difficult for the stock this earnings season.
Notably, Sell-rated stocks (#4 or 5) going into an earnings announcement are best avoided.
Catalyst Pharmaceuticals, Inc. Price and EPS Surprise
Catalyst Pharmaceuticals, Inc. Price and EPS Surprise | Catalyst Pharmaceuticals, Inc. Quote
Stocks That Warrant a Look
Here are some stocks worth considering as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Ultragenyx Pharmaceuticals Inc. RARE has an Earnings ESP of +6.36% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Amicus Therapeutics, Inc. FOLD has an Earnings ESP of +24.59% and a Zacks Rank of 3. The company is scheduled to release first-quarter 2019 results on May 8.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report
Endo International plc (ENDP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research